Molnupiravir Modestly Reduces Risk For Severe COVID-19 Symptoms And May Also Reduce Risk For Long COVID, Results Show

Healio (9/18, Feller) reports treatment with “antiviral molnupiravir modestly reduces the risk for severe symptoms of COVID-19 and may also reduce the risk for long COVID, according to” researchers who “randomly assigned more than 25,000 adults to receive either molnupiravir plus usual care (12,821) or only usual care (12,962).” Results showed that “among participants in the treatment arm, molnupiravir was associated with a 1.9% reduction in severity of any severe symptoms and a 2.5% reduction in severity of persistent symptoms after 6 months.” The Lancet published the results.